Tadalafil once daily in the treatment of lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) in men without erectile dysfunction

BJU International

Volumn 112, Issue 7, 2013, Pages 990-997

  Brock, Gerald ^a   Broderick, Gregory ^b   Roehrborn, Claus G ^c   Xu, Lei ^d   Wong, David ^d   Viktrup, Lars ^d  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d ELI LILLY AND COMPANY   (United States)

Author keywords

BPH; erectile dysfunction; lower urinary tract symptoms; LUTS; phosphodiesterase type 5 inhibitors; prostatic hyperplasia; tadalafil

Indexed keywords

PLACEBO; TADALAFIL;

ADULT; ARTICLE; BACKACHE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; ERECTILE DYSFUNCTION; GASTROESOPHAGEAL REFLUX; HEADACHE; HUMAN; HYPERTENSION; INTERNATIONAL PROSTATE SYMPTOM SCORE; LIMB PAIN; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; MALE; MICTURITION; MULTICENTER STUDY; MYALGIA; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS;

BPH; ERECTILE DYSFUNCTION; LOWER URINARY TRACT SYMPTOMS; LUTS; PHOSPHODIESTERASE TYPE 5 INHIBITORS; PROSTATIC HYPERPLASIA; TADALAFIL;

CARBOLINES; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; ERECTILE DYSFUNCTION; HUMANS; LOWER URINARY TRACT SYMPTOMS; MALE; MIDDLE AGED; PHOSPHODIESTERASE 5 INHIBITORS; PROSTATIC HYPERPLASIA;

EID: 84886096903     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/bju.12251     Document Type: Article

References (34)

1. Jacobsen SJ, Girman CJ, Guess HA, et al. Natural history of prostatism: factors associated with discordance between frequency and bother of urinary symptoms. Urology 1993; 42: 663-671
2. Norman RW, Nickel JC, Fish D, Pickett SN,. 'Prostate-related symptoms' in Canadian men 50 years of age or older: prevalence and relationships among symptoms. Br J Urol 1994; 74: 542-550
3. Sagnier PP, MacFarlane G, Teillac P, Botto H, Richard F, Boyle P,. Impact of symptoms of prostatism on level of bother and quality of life of men in the French community. J Urol 1995; 153 (3 Pt 1): 669-673
4. McVary KT,. BPH: epidemiology and comorbidities. Am J Manag Care 2006; 12 (5 Suppl.): S122-128
5. Rosen R, Altwein J, Boyle P, et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol 2003; 44: 637-649
6. Casabe AR, Roehrborn C, Da Pozza LF, et al. Combination therapy with finasteride and tadalafil once daily for 6 months: a randomized, placebo-controlled study in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol 2013; 12 (Suppl): e1096
7. Kaplan SA,. Update on the American Urological Association guidelines for the treatment of benign prostatic hyperplasia. Rev Urol 2006; 8 (Suppl. 4): S10-17
8. Schulman CC,. Lower urinary tract symptoms/benign prostatic hyperplasia: minimizing morbidity caused by treatment. Urology 2003; 62 (3 Suppl. 1): 24-33
9. Hellstrom WJ, Sikka SC,. Effects of acute treatment with tamsulosin versus alfuzosin on ejaculatory function in normal volunteers. J Urol 2006; 176 (4 Pt 1): 1529-1533
10. ® (Tamsulosin) [Package Insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc, 2009. Available at: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6db9cdec-0833-4391-8764- 079ce6f7e4d1. Accessed July 2013
11. ® (Silodosin) [Package Insert]. Corona, CA: Watson Pharmaceuticals, Inc, 2011. Available at: http://dailymed.nlm.nih.gov/dailymed/ lookup.cfm?setid=96425d91-cfe1-477d-a130-b58c330ca8a3. Accessed July 2013
12. McConnell JD, Roehrborn CG, Bautista OM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003; 349: 2387-2398
13. AUA Practice Guidelines Committee. AUA guideline on the management of benign prostatic hyperplasia, chapter 1: diagnosis and treatment recommendations. Available at: http://www.auanet.org/common/pdf/education/Arc- BPH-Chapter1.pdf. Revised 2003. Accessed July 2013
14. US Food and Drug Administration, US Department of Health and Human Services. Questions and Answers: Finasteride Label Changes. Available at: http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm299754.htm. Revised April 2012. Accessed July 2013
15. ® (Finasteride) [Package Insert]. Whitehouse Station, NJ: Merck & Co, Inc, 2012. Available at: http://dailymed.nlm.nih. gov/dailymed/lookup.cfm?setid=7c01f541-1c88-400c-41a9-7cbb9dee50c0. Accessed July 2013
16. Egerdie RB, Auerbach S, Roehrborn CG, et al. Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo-controlled, double-blind study. J Sex Med 2012; 9: 271-281
17. Roehrborn CG, McVary KT, Elion-Mboussa A, Viktrup L,. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. J Urol 2008; 180: 1228-1234
18. Porst H, Kim ED, Casabé AR, et al. Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial. Eur Urol 2011; 60: 1105-1113
19. Oelke M, Giuliano F, Mirone V, Cox D, Viktrup L,. Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial. Eur Urol 2012; 61: 917-925
20. Broderick GA, Brock GB, Roehrborn CG, Watts SD, Elion-Mboussa A, Viktrup L,. Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia in men with or without erectile dysfunction. Urology 2010; 75: 1452-1458
21. McVary KT, Roehrborn CG, Kaminetsky JC, et al. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 2007; 177: 1401-1407
22. AUA Practice Guidelines Committee. American Urological Association guideline: on the management of benign prostatic hyperplasia (BPH). Available at: http://www.auanet.org/education/guidelines/benign-prostatic-hyperplasia.cfm. Revised 2010. Accessed July 2013
23. Koskimäki J, Shiri R, Tammela T, Häkkinen J, Hakama M, Auvinen A,. Regular intercourse protects against erectile dysfunction: Tampere Aging Male Urologic Study. Am J Med 2008; 121: 592-596
24. Porst H, McVary KT, Montorsi F, et al. Effects of once-daily tadalafil on erectile function in men with erectile dysfunction and signs and symptoms of benign prostatic hyperplasia. Eur Urol 2009; 56: 727-735
25. Jacobsen SJ, Jacobson DJ, Rohe DE, Girman CJ, Roberts RO, Lieber MM,. Frequency of sexual activity and prostatic health: fact or fairy tale? Urology 2003; 61: 348-353
26. Andersson KE, de Groat WC, McVary KT, et al. Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: pathophysiology and mechanism(s) of action. Neurourol Urodyn 2011; 30: 292-301
27. Giuliano F, Uckert S, Maggi M, Birder L, Kissel J, Viktrup L,. The mechanism of action of phosphodiesterase type 5 inhibitors in the treatment of Lower Urinary Tract Symptoms Related to Benign Prostatic Hyperplasia. Eur Urol 2012; 63: 506-516
28. Morelli A, Filippi S, Comeglio P, et al. Acute vardenafil administration improves bladder oxygenation in spontaneously hypertensive rats. J Sex Med 2010; 7 (1 Pt 1): 107-120
29. Morelli A, Sarchielli E, Comeglio P, et al. Phosphodiesterase type 5 expression in human and rat lower urinary tract tissues and the effect of tadalafil on prostate gland oxygenation in spontaneously hypertensive rats. J Sex Med 2011; 8: 2746-2760
30. ® (Tadalafil) [Package Insert]. Indianapolis, IN: Lilly USA, LLC, 2011. Available at: http://dailymed.nlm.nih.gov/dailymed/lookup. cfm?setid=bcd8f8ab-81a2-4891-83db-24a0b0e25895. Accessed July 2013
31. Fusco F, di Villa Bianca Rd, Mitidieri E, Cirino G, Sorrentino R, Mirone V,. Sildenafil effect on the human bladder involves the L-cysteine/hydrogen sulfide pathway: a novel mechanism of action of phosphodiesterase type 5 inhibitors. Eur Urol 2012; 62: 1174-1180
32. Minagawa T, Aizawa N, Igawa Y, Wyndaele JJ,. Inhibitory effects of phosphodiesterase 5 inhibitor, tadalafil, on mechanosensitive bladder afferent nerve activities of the rat, and on acrolein-induced hyperactivity of these nerves. BJU Int 2012; 110 (6 Pt B): E259-266
33. Rosen RC, Cappelleri JC, Gendrano N 3rd,. The International Index of Erectile Function (IIEF): a state-of-the-science review. Int J Impot Res 2002; 14: 226-244
34. Giuliano F, Viktrup L,. Reply from Authors re: Steven A. Kaplan. Tadalafil for the Treatment of Benign Prostatic Hyperplasia: when the Moment Does Not Add Up. Eur Urol 2013; 63: 517-8: Tadalafil in the Treatment of Men with Lower Urinary Tract Symptoms and/or Erectile Dysfunction Symptoms. Eur Urol 2013; 63: 519-520